Journal Home
Search for

Volume 58, Issue 5, Pages 781-786 (May 2008)


View previous. 15 of 50 View next.

Acne and oral contraceptives: Update on women's health screening guidelines

Jason E. Frangos, BAa, Christina N. Alavian, MDb, Alexa B. Kimball, MD, MPHcCorresponding Author Informationemail address

Accepted 28 December 2007. published online 25 March 2008.

Oral contraceptives (OCs) have been shown to be safe and effective for the treatment of acne in most women of childbearing potential, and several have been approved by the Food and Drug Administration for this purpose. However, dermatologists have historically been reluctant to prescribe OCs for acne because of long-standing recommendations requiring a preliminary pelvic examination and Papanicolaou smear before initiation of therapy. In recent guideline shifts, expert panels and major health organizations have reached a consensus that OC provision no longer necessitates the performance of a pelvic examination and Papanicolaou smear. These new guideline revisions could change the way dermatologists treat acne in their healthy female patients of child-bearing age.

a The Yale University School of Medicine, New Haven, Connecticut

b University of Massachusetts Medical School, Boston, Massachusetts

c Harvard Medical School, Boston, Massachusetts

Corresponding Author InformationReprint requests: Alexa B. Kimball, MD, MPH, Director, Clinical Unit for Research Trials in Skin, Massachusetts General Hospital, 50 Staniford St, #246 Dermatology, Boston, MA 02114.

 Funding sources: None.

 Disclosure: Dr Kimball is a consultant to Intendis. Mr Frangos and Dr Alavian have no conflicts of interest to declare.

PII: S0190-9622(08)00135-7

doi:10.1016/j.jaad.2007.12.040


View previous. 15 of 50 View next.